Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,066 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia.
Wada T, Hara A, Muso E, Maruyama S, Kato S, Furuichi K, Yoshimura K, Toyama T, Sakai N, Suzuki H, Tsukamoto T, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Goto S, Sakamaki Y, Yokoyama H, Mori N, Tanaka S, Yuzawa Y, Hasegawa M, Matsubara T, Wada J, Tanabe K, Masutani K, Abe Y, Tsuruya K, Fujimoto S, Iwatsubo S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Sofue T, Miyata H, Nakano T, Ohtake T, Kobayashi S; LICENSE study Group. Wada T, et al. Among authors: abe m, abe y. Clin Exp Nephrol. 2021 Jan;25(1):1-8. doi: 10.1007/s10157-020-01959-9. Epub 2020 Aug 28. Clin Exp Nephrol. 2021. PMID: 32857255
Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia.
Wada T, Muso E, Maruyama S, Hara A, Furuichi K, Yoshimura K, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Yokoyama H, Mori N, Yuzawa Y, Matsubara T, Tsukamoto T, Wada J, Ito T, Masutani K, Tsuruya K, Fujimoto S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Kobayashi S. Wada T, et al. Among authors: abe m. Clin Exp Nephrol. 2018 Jun;22(3):591-596. doi: 10.1007/s10157-017-1488-4. Epub 2017 Oct 27. Clin Exp Nephrol. 2018. PMID: 29080119 Clinical Trial.
Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H, Yoshida Y, Nagura C, Furukawa T, Tei R, Maruyama T, Maruyama N, Abe M. Takashima H, et al. Among authors: abe m. Diab Vasc Dis Res. 2018 Sep;15(5):469-472. doi: 10.1177/1479164118782872. Epub 2018 Jun 20. Diab Vasc Dis Res. 2018. PMID: 29923427 Free article. Clinical Trial.
Clinical and histological features in pediatric and adolescent/young adult patients with renal disease: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR).
Urushihara M, Sato H, Shimizu A, Sugiyama H, Yokoyama H, Hataya H, Matsuoka K, Okamoto T, Ogino D, Miura K, Hamada R, Hibino S, Shima Y, Yamamura T, Kitamoto K, Ishihara M, Konomoto T, Hattori M; the Committee for Renal Biopsy and Disease Registry of the Japanese Society of Nephrology. Urushihara M, et al. Clin Exp Nephrol. 2021 Sep;25(9):1018-1026. doi: 10.1007/s10157-021-02077-w. Epub 2021 May 28. Clin Exp Nephrol. 2021. PMID: 34047871
Performance Status Modifies the Association Between Vitamin D Receptor Activator and Mortality or Fracture: A Prospective Cohort Study on the Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry.
Murashima M, Hamano T, Nishiyama T, Tsuruya K, Ogata S, Kanda E, Abe M, Masakane I, Nitta K. Murashima M, et al. Among authors: abe m. J Bone Miner Res. 2022 Aug;37(8):1489-1499. doi: 10.1002/jbmr.4621. Epub 2022 Jul 8. J Bone Miner Res. 2022. PMID: 35689819 Free article.
6,066 results